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Ecto-ADP-ribosyltransferase 
ARTC2.1 functionally modulates 
FcγR1 and FcγR2B on murine 
microglia
Björn Rissiek1, Stephan Menzel2, Mario Leutert  3, Maike Cordes1, Sarah Behr1, Larissa Jank1, 
Peter Ludewig1, Mathias Gelderblom1, Anne Rissiek2, Sahil Adriouch  2,4, Friedrich Haag2, 
Michael O. Hottiger3, Friedrich Koch-Nolte2 & Tim Magnus1
Mammalian ecto-ADP-ribosyltransferases (ecto-ARTs or also ARTCs) catalyze the ADP-ribosylation 
of cell surface proteins using extracellular nicotinamide adenine dinucleotide (NAD+) as substrate. 
By this post-translational protein modification, ecto-ARTs modulate the function of various target 
proteins. A functional role of ARTC2 has been demonstrated for peripheral immune cells such as T 
cells and macrophages. Yet, little is known about the role of ecto-ARTs in the central nervous system 
and on microglia. Here, we identified ARTC2.1 as the major ecto-ART expressed on murine microglia. 
ARTC2.1 expression was strongly upregulated on microglia upon co-stimulation with LPS and an 
ERK1/2 inhibitor or upon IFNβ stimulation. We identified several target proteins modified by ARTC2.1 
on microglia with a recently developed mass spectrometry approach, including two receptors for 
immunoglobulin G (IgG), FcγR1 and FcγR2B. Both proteins were verified as targets of ARTC2.1 in vitro 
using a radiolabeling assay with 32P-NAD+ as substrate. Moreover, ADP-ribosylation of both targets 
strongly inhibited their capacity to bind IgG. In concordance, ARTC2.1 induction in WT microglia and 
subsequent cell surface ADP-ribosylation significantly reduced the phagocytosis of IgG-coated latex 
beads, which was unimpaired in NAD+/DTT treated microglia from ARTC2.1−/− mice. Hence, induction 
of ARTC2.1 expression under inflammatory conditions, and subsequent ADP-ribosylation of cell surface 
target proteins could represent a hitherto unnoticed mechanism to regulate the immune response of 
murine microglia.
Mammalian ecto-ADP-ribosyltransferases (ARTs) are cell surface enzymes that catalyze the covalent transfer of 
the ADP-ribose moiety from nicotinamide adenine dinucleotide (NAD+) to arginine residues on their target pro-
teins1. Owing to their structural relation to clostridial toxins C2 and C3, mammalian ecto-ARTs are abbreviated 
“ARTCs”, whereas intracellular ARTs structurally related to diphtheria toxin are abbreviated “ARTDs” (formerly 
poly-ADP-ribosyltransferases (PARPs))2.
The murine ARTC family comprises 6 members, ARTC1-5 including two isoforms of ARTC2 (ARTC2.1 
and ARTC2.2) that are encoded by two closely linked genes (Art2a and Art2b)3. ARTC2.1 and ARTC2.2 display 
approximately 78% sequence identity. Interestingly, ARTC2.1 contains an extra allosteric disulfide bond and is 
active only under mild reducing conditions4. Art2a and Art2b are known to be differentially expressed among 
common laboratory mouse strains. While BALB/c mice functionally express both genes, a nonsense mutation in 
Art2a results in the absence of the ARTC2.1 enzyme in the C57BL/6 strain and a deletion of the Art2b gene results 
in absence of the ARTC2.2 enzyme in the NZW strain5–7. Both ARTC2 isoforms are prominently expressed on 
immune cells. While T cells predominantly express Art2b and, to a lower extent, Art2a, antigen presenting cells 
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such as macrophages and dendritic cells only express Art2a. Interestingly, macrophage cell surface expression of 
ARTC2.1 can be strongly increased by priming the cells with proinflammatory mediators including agonists for 
Toll-like receptors (TLRs) and type I and type II interferons, suggesting that ARTC2.1 regulates cell responses 
during inflammatory conditions8.
Several ARTC2 target proteins have been identified at the surface of immune cells and the functional con-
sequences of their ADP-ribosylation have been investigated. In case of the ligand-gated ion channel P2X7, 
ADP-ribosylation at arginine position 125 (Arg125) leads to its activation by providing a covalently attached 
ADP-ribose ligand in the vicinity of the ligand-binding pocket9–11. For several other ARTC2 targets, including 
LFA-1, CD8a, and CD25, ADP-ribosylation has been shown to inhibit binding to their natural ligands12–15. Hence, 
ADP-ribosylation of target proteins at the surface of immune cells by ART2 ecto-enzymes constitutes an impor-
tant post-translational mechanism to regulate cell surface protein function and, thereby, immune cell functions.
Microglia are local innate immune cells of the central nervous system that exhibit similar properties as periph-
eral macrophages16. They can phagocytose invading pathogens or necrotic cells following ischemia, and they 
respond to pathogenic insults with the release of proinflammatory cytokines17. Even though the role of micro-
glia in brain inflammation has been extensively studied, little is known about the expression and function of 
ecto-ARTs on these cells. The aims of this study were to characterize the expression and the activity of ARTC2 
on microglia, to identify potential target proteins of ARTC2, and to study the functional consequences of their 
ADP-ribosylation. We found that ARTC2.1 expression on microglia is upregulated under inflammatory condi-
tions and, using a novel mass spectrometry approach18, we identified FcγR1 and FcγR2B as prominent targets that 
are functionally inhibited by ADP-ribosylation.
Results
Ecto-ADP-ribosyltransferase activity is detectable on a small fraction of microglia from mixed 
glial cell cultures. To monitor expression of ARTC2 isoforms on the cell surface of microglia we used mono-
clonal antibodies (mAbs) that specifically detect ARTC2.1 (clone R18-A136) or ARTC2.2 (clone NIKA-A102)7,19. 
With these we analyzed immune cells from BALB/c WT mice or ARTC2.1- and ARTC2.2-deficient BALB/c mice 
as respective negative controls. First, we confirmed the specificity of both ARTC2-specific mAbs on spleen F4/80+ 
macrophages, known to predominantly express ARTC2.1 and on spleen CD3e+ T cells, known to express high 
levels of ARTC2.2 (Fig. 1a). Indeed, by using ARTC2.1- and ARTC2.2-specific mAbs in flow cytometry analyses 
we confirmed the expression of ARTC2.1 on macrophages of WT but not ARTC2.1−/− mice and the expression 
of ARTC2.2 on T cells of WT but not ARTC2.2−/− mice. We then used the same isoform-specific mAbs to explore 
the expression of ARTC2.1/ARTC2.2 on CD11b+GLAST− microglia obtained from mixed glial cell cultures. 
Using flow cytometry, we detected little if any ARTC2.1 expression on WT microglia compared to ARTC2.1−/− 
microglia, while the ARTC2.2 expression was virtually absent on both, WT and ARTC2.2−/− microglia (Fig. 1a).
Figure 1. Ecto-ART expression and activity on microglia from mixed glial cell cultures. (a) Reactivity of 
fluorochrome-conjugated ARTC2.1 and ARTC2.2-specific mAbs was analyzed by flow cytometry of BALB/c 
WT spleen CD3+ T cells, F4/80+ macrophages (MΦ). or CD11b+GLAST− microglia from BALB/c WT mixed 
glial cell cultures. BALB/c ARTC2.1−/− and ARTC2.2−/− cells were used as negative controls. (b) Etheno-
NAD (eNAD+) can be used as surrogate substrate for ARTC2, which etheno-ADP-ribosylates cell surface 
proteins. This can be detected by use of etheno-adenosine-specific mAb 1G4. Ecto-ART activity was analyzed 
by measuring etheno-ADP-ribosylation of cell surface proteins on BALB/c WT and ARTC2.1−/− spleen MΦ 
(upper panel) and on microglia from mixed glial cell cultures (lower panel) after incubating cells with 100 µM 
eNAD+ (blue), with 100 µM eNAD+ and 2 mM DTT (red) or without additions (grey). Etheno-ADP-ribosylated 
proteins were detected with mAb 1G4. Data are representative of 3 independent experiments.
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We next used a more sensitive approach to detect the presence of ADP-ribosyltransferases (ART) enzymatic 
cell surface activity. Incubation of cells with the ARTC2 surrogate substrate etheno-nicotinamide adenine dinu-
cleotide (eNAD+) induces the etheno-ADP-ribosylation (eADPR) of cell surface proteins catalyzed by ARTC2. 
The mAb 1G4 was then used to detect the eADPR cell surface proteins using flow cytometry20 (Fig. 1b). We first 
performed this assay using F4/80+ splenic macrophages. As expected, F4/80+ macrophages from WT mice exhib-
ited a robust cell surface ART enzymatic activity that was further increased in the presence of the reducing agent 
dithiothreitol (DTT), a known enhancer of ARTC2.1 enzymatic activity21. In contrast, there was no detectable 
ART activity on macrophages of ARTC2.1−/− mice (Fig. 1b). We next used the same methodology to monitor 
the enzymatic ART activity on microglia from mixed glial cell cultures. We observed that only a small fraction 
of microglia from WT mice exhibited cell surface ART activity in the presence of eNAD+/DTT (Fig. 1b). This 
enzymatic activity was virtually absent on microglia derived from ARTC2.1−/− mice under the tested conditions. 
Hence, these results suggest a low, but enzymatically detectable, expression of ARTC2.1 at the surface of a subset 
of microglia.
ARTC2.1 expression can be induced in microglia by co-stimulation with LPS and U0126. It 
has been described that macrophage stimulation with lipopolysaccharide (LPS) increases the expression of 
ARTC2.1 which can be further amplified by the ERK1/2 inhibitor U0126 (Sigma)8,22. Therefore, it is conceivable 
that ARTC2.1 expression on microglia can be enhanced by similar mechanisms. We thus stimulated mixed glial 
cells with LPS in the presence of U0126 for 24 h, and then evaluated the ART enzymatic activity present at the cell 
surface by flow cytometry. LPS treatment alone did not increase cell surface ART activity on microglia compared 
to untreated controls and U0126 alone only led to a slight increase of enzymatic activity on microglia. However, 
combined stimulation with LPS and U0126 resulted in a robust increase in cell surface ART activity on microglia 
(Fig. 2a). To further validate this finding, we incubated LPS/U0126 treated mixed glial cells with radioactive 
32P-NAD+ in the presence or absence of DTT, lysed the cells and analyzed the solubilized proteins for incorpo-
rated radioactivity by SDS-PAGE autoradiography. We observed multiple prominent bands (I–VI) when cells 
were incubated with 32P-NAD+ in the presence of DTT, suggesting ADP-ribosylation of multiple target proteins 
(Fig. 2b). Further, we separated microglia and astrocytes from LPS/U0126 stimulated mixed glial cell cultures by 
FACS sorting, before incubation with radioactive 32P-NAD+/DTT and analysis of proteins by SDS-PAGE autora-
diography. We observed a similar pattern of ADP-ribosylated proteins for microglia as observed for mixed glial 
Figure 2. ARTC2.1 is upregulated on microglia upon stimulation with LPS and U0126. (a) Mixed glial cells 
were stimulated with or without LPS (0.1 µg/ml), U0126 (10 µM) or both for 24 h, followed by incubation with 
eNAD+ (50 µM) and DTT (2.5 mM) for 15 min. Etheno-ADP-ribosylated cell surface proteins were detected 
with mAb 1G4 (displayed as mean fluorescence intensity, MFI). (b) Mixed glial cell cultures were stimulated 
with LPS (0.1 µg/ml) and U0126 (10 µM) for 24 h. Total cells (left) or FACS sorted astrocytes and microglia 
(right) were then incubated for 15 min with radioactive 32P-NAD+ (1 µM) in the presence or absence of DTT 
(2.5 mM). Cells were lysed, proteins were size fractioned by SDS PAGE and subjected to autoradiography. 
(c) Mixed glial cells from BALB/c WT and ARTC2.1−/− mice were stimulated with LPS (0.1 µg/ml) and 
U0126 (10 µM) for 24 h, and then incubated with eNAD+ (50 µM) and DTT (2.5 mM) for 15 min. Etheno-
ADP-ribosylated surface proteins were detected with mAb 1G4. (d) mRNA levels of Art2a from FACS sorted 
microglia (n = 5 individual experiments) of unstimulated or LPS/U0126 stimulated mixed glial cell cultures 
were determined by quantitative real-time PCR. (e) Surface expression of ARTC2.1 by microglia of LPS/
U0126 stimulated or control mixed glial cell cultures of BALB/c WT or ARTC2−/− mice was analyzed by flow 
cytometry as in Fig. 1c. Data are representative of 2–3 independent experiments.
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cells, whereas astrocytes barely showed any ADP-ribosylation of cell surface proteins, indicating that microglia 
are the main source of cell surface ART activity in the mixed glial cell culture (Fig. 2b). As the enzymatic activity 
of ARTC2.1, in contrast to that of ARTC2.2, is strongly enhanced under reducing conditions, the absence of 
detectable ADP-ribosylated proteins in samples that were not treated with DTT suggested that ARTC2.1 was the 
main ecto-ART expressed by microglia. To further test this hypothesis, we repeated the experiment with mixed 
glial cells derived from ARTC2.1−/− mice. The results show that microglia from ARTC2.1−/− mice did not exhibit 
any detectable cell surface ART activity after LPS/U0126 stimulation(Fig. 2c).
We next investigated the upregulation of ARTC2.1 in microglia upon LPS/U0126 treatment. Quantification of 
Art2a mRNA by qRT-PCR analyses of FACS sorted microglia revealed a more than 100-fold higher level of Art2a 
mRNA in cells treated with LPS/U0126 versus untreated control cells (Fig. 2d). Using the ARTC2.1-specific mAb 
R18-A136 we confirmed the enhanced cell surface expression of ARTC2.1 on microglia after LPS/U0126 treat-
ment (Fig. 2e). Taken together, the results show that ARTC2.1 on microglia is strongly upregulated by LPS/U0126 
treatment, enabling ADP-ribosylation of multiple target proteins on microglia in the presence of the ARTC2.1 
substrate NAD+.
ARTC2.1 expression in microglia can be induced by IFNβ stimulation. IFNβ has been described as 
a key cytokine driving the expression of ARTC2.1 in macrophages upon LPS/U0126 stimulation8. To test whether 
IFNβ is also expressed by LPS/U0126 stimulated microglia obtained from mixed glial cell cultures we first meas-
ured Ifnb1 mRNA expression in sorted microglia from LPS/U0126 stimulated cultures. Here, we detected a signif-
icant upregulation of Ifnb1 when compared to unstimulated controls (Fig. 3a). Further, we detected significantly 
increased levels of soluble IFNβ in the supernatants of these LPS/U0126 stimulated mixed glial cells (Fig. 3b). 
Next, we tested if IFNβ alone was able to induce ecto-ART activity in microglia. Indeed, IFNβ stimulated micro-
glia exhibited a dose-dependent increase of cell surface eADP-ribosylation after incubation with eNAD+/DTT 
(Fig. 3c). The IFNβ induced ecto-ART activity was ARTC2.1-dependent since ARTC2.1−/− microglia did not 
show any increase in ecto-ART activity after INFβ stimulation (Fig. 3d). Using specific monoclonal antibodies, 
we could confirm an increase in ARTC2.1 expression on IFNβ stimulated microglia, when compared to unstim-
ulated controls (Fig. 3e). In summary, IFNβ induced ecto-ART activity on microglia by increasing the cell surface 
expression of ARTC2.1.
Identification of ARTC2.1 target proteins on microglia by mass spectrometry. In order to iden-
tify the targets of ARTC2.1 on microglia, we used a newly developed mass spectrometry-based strategy18. For 
this, microglia from LPS/U0126 treated WT and ARTC2.1−/− mixed glial cell cultures were sorted by FACS 
and incubated with NAD+/DTT. Cells were lysed, peptides were generated from the isolated proteins by trypsin 
digestion and the ADP-ribosylated peptides enriched using the ADPR-binding macrodomain Af1521 (Fig. 4a). 
Subsequent mass spectrometry analyses (LC-MS/MS) revealed 54 unique, ADP-ribosylated peptides correspond-
ing to 40 distinct cell surface target proteins on WT microglia (Table 1, Fig. 4b). Importantly, no ADP-ribosylated 
peptides were detected in samples of microglia from ARTC2.1−/− mice, confirming the specificity of the method. 
Most identified targets were ADP-ribosylated on one site (30 targets), seven on two sites (Alcam, Clec12a, Enpp1, 
Icam1, Ptprc, Slc3a2, Tfrc), two on three sites (Fcgr2b, Itgb5) and one on four sites (Itgam). The majority of the 
detected ADP-ribosylated peptides were ADP-ribosylated on arginine residues (43 peptides), followed by gluta-
mate (6 peptides) and aspartate (5 peptides) residues. Most of the newly identified ARTC2.1 targets are involved 
in cell-cell or cell-matrix interaction processes. However, some targets are also directly related to regulation of 
immune cell function such as detection of pathogen associated molecular pattern (CD14, Tlr2), phagocytosis 
(Mrc1), antigen presentation (H2-D1, H2-K1) or binding of immunoglobulines (FcεR1, FcγR1, FcγR2B).
ADP-ribosylation of FcγR1 and FcγR2B diminishes binding of IgG. We were particularly intrigued 
by the discovery of two immunoglobulin G (IgG) receptors FcγR1 and FcγR2B as targets of ARTC2.1 and set 
out to address the question whether ARTC2.1-mediated modification of these proteins impinges on their func-
tion. In silico structural analyses of the observed ADP-ribosylation sites of FcγR1 (R184) and FcγR2B (R158, 
R198) revealed that these sites lie in close proximity to the binding site of the Fc portion of IgG, suggesting a 
potential influence of ADP-ribosylation at these sites on IgG binding (Fig. 5a). To test this possibility, we estab-
lished a microscale thermophoresis assay for IgG binding to soluble FcγR1 and FcγR2B. First, we validated 
the ADP-ribosylation of both soluble FcγRs by SDS-PAGE autoradiography after co-incubation with soluble 
ARTC2.1 and 32P-NAD+/DTT. The results confirmed that ARTC2.1 ADP-ribosylates both FcγRs and that this 
was inhibited by the ARTC inhibitor novobiocin (Fig. 5b). Interestingly, FcγR2B showed a more pronounced 
ADPR signal compared to FcγR1, consistent with ADP-ribosylation on more than one site. We then used highly 
concentrated human intravenous immunoglobulins (IVIGs), known to bind to murine FcγR1 and FcγR2B23, and 
probed the impact of ADP-ribosylation on IgG binding to FcγRs. When FcγRs were preincubated with NAD+/
DTT in the presence of ARTC2.1, microscale thermophoresis analysis indeed revealed a 3.2-fold diminished IgG 
binding to FcγR1 and a 2.5-fold reduced binding to FcγR2B (Fig. 5c). To strengthen this finding, we transiently 
transfected human embryonic kidney (HEK) cells with FcγR1 or FcγR2B expression plasmids alone or in combi-
nation with an ARTC2.1 expression plasmid (Fig. 5d). FcγR/ARTC2.1 co-transfected HEK cells exhibited robust 
cell surface ADP-ribosylation upon incubation with eNAD+/DTT (Fig. 5e). Of note, HEK cells were incubated 
with or without NAD+/DTT to induce cell surface ADP-ribosylation prior to addition of diluted IgG-containing 
mouse serum. Moreover, we did not detect any impact of the reducing agent DTT on IgG binding to FcγR1 and 
FcγR2B single transfected HEK cells (Fig. 5f). Co-transfection of FcγR1 or FcγR2B with ARTC2.1, however, led 
to an almost complete reduction of IgG binding to the HEK cells when cells were pretreated with NAD+/DTT, 
confirming that ADP-ribosylation of FcγR1 and FcγR2B diminishes IgG binding. In summary, we confirmed 
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FcγR1 and FcγR2B as targets of ARTC2.1-mediated ADP-ribosylation and demonstrated that the covalent attach-
ment of the ADP-ribose group to both FcγRs impinges on their binding to IgG.
Cell surface ADP-ribosylation on microglia diminishes IgG binding and phagocytosis of 
IgG-coated beads. We next analyzed the influence of cell surface ADP-ribosylation on IgG binding by LPS/
U0126 or IFNβ treated microglia. For this, we incubated LPS/U0126 stimulated, IFNβ stimulated or unstimulated 
mixed glial cells with IgG-containing mouse serum and analyzed binding of IgG to these cells by flow cytometry 
using fluorochrome-conjugated F(ab)2 anti-mouse IgG. We observed a reduced binding of murine IgG to either 
LPS/U0126 or IFNβ treated microglia when cells were pre-incubated with NAD+/DTT (Fig. 6a). Conversely, 
unstimulated microglia did not exhibit a comparable shift in IgG binding upon pre-incubation with NAD+/DTT.
Finally, we probed the impact of microglia cell surface ADP-ribosylation on FcγR-mediated phagocytosis. For 
this, we stimulated WT microglia with LPS/U0126 or IFNβ for 24 h to induce ecto-ART activity. Cells were then 
incubated for 30 min with NAD+/DTT or with DTT alone to exclude a potential impact of the reducing agent 
DTT on the phagocytic capacity of the microglia. We then washed the cells and added PE-labeled IgG-coated 
latex beads to the culture. The analyses of phagocytosis by flow cytometry revealed that the NAD+/DTT incu-
bation diminished phagocytosis of IgG beads by LPS/U0126 or IFNβ stimulated microglia by about 25% when 
compared to unstimulated controls (Fig. 6b). This effect was virtually absent in ARTC2.1−/− microglia treated in 
a similar fashion. Together, these findings suggest a functional role of ARCT2.1-mediated ADP-ribosylation of 
FcγRs on microglia by regulating IgG-dependent phagocytosis.
Discussion
In this study we demonstrated that murine microglia express ecto-ADP-ribosyltransferase ARTC2.1, which is 
strongly upregulated under LPS treatment and simultaneous inhibition of the ERK1/2 signaling pathway or by 
stimulation with IFNβ. In the presence of NAD+ and reducing conditions this leads to the ARTC2.1-dependent 
ADP-ribosylation of numerous cell surface proteins. We used mass spectrometry to search for new ARTC2.1 
Figure 3. ARTC2.1 is upregulated on microglia upon stimulation with IFNβ. (a) mRNA levels of Ifnb1 from 
FACS sorted microglia (n = 5 individual experiments) of unstimulated or LPS/U0126 stimulated mixed glial 
cell cultures were determined by quantitative real-time PCR. (b) IFNβ levels in the supernatant of unstimulated, 
LPS stimulated or LPS/U0126 stimulated mixed glial cells were determined by ELISA. (c) Ecto-ART activity on 
microglia from mixed glial cells was measured by using eNAD+/1G4 in response to 24 h stimulation with rising 
concentrations of IFNβ (1–1000 U). (d) Induction of ecto-ART activity upon IFNβ stimulation was compared 
in BALB/c WT and ARTC2.1−/− microglia. (e) Upregulation of ARTC2.1 expression on microglia upon 
IFNβ stimulation was measured using an ARTC2.1-specific mAb in comparison to isotype control. Data are 
representative of 2–3 independent experiments. Statistical comparison of two groups was performed by using 
the student’s t test (p < 0.05 = */p < 0.01 = **/p < 0.001 = ***).
www.nature.com/scientificreports/
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targets and identified 40 ADP-ribosylated cell surface proteins on microglia, most of them being associated 
with microglia immune function such as adhesion, sensing of pathogen associated molecular patterns, anti-
gen presentation and immunoglobulin binding. In a proof-of-principle experiment we were able to show that 
ADP-ribosylation of FcγR1 and FcγR2B functionally inhibited cell surface IgG binding and phagocytosis of 
IgG-coated beads in microglia.
ARTC2 expression in murine immune cells has been reported in previous studies. Antigen presenting cells 
such as macrophages and dendritic cells preferentially express ARTC2.1, whereas T cells can express both, 
ARTC2.1 and ARTC2.222. Studies have shown that bone marrow-derived macrophages (BMDM) strongly upreg-
ulate cell surface ARTC2.1 upon proinflammatory stimulation with LPS in combination with ERK1/2 inhibition8. 
One proposed mechanism underlying ARTC2.1 upregulation in BMDM is the release of IFN-β, which stimulates 
BMDM in an autocrine fashion. Indeed, we could demonstrate that LPS/U0126 stimulation induces IFNβ expres-
sion in microglia and that microglia stimulated with IFNβ alone exhibit a pronounced, ARTC2.1-dependent, 
ecto-ART activity. Another recent study has shown that injection of the Toll-like receptor 3 agonist polyI:C 
induced IFNβ expression in microglia in vivo. This suggests that proinflammatory triggers could potentially 
induce upregulation of ARTC2.1 in microglia in vivo24.
The upregulation of ARTC2.1 on microglia under inflammatory conditions could represent a new way of 
fine-tuning microglia immune responses. However, ARTC2.1 needs reducing conditions to unlock its enzymatic 
activity. Extracellular antioxidants such as glutathione or ascorbic acid have been found in rodent brains25 and 
therefore potentially could serve as reducing agents for ARTC2.1 expressed on brain microglia. Interestingly, 
release of antioxidants is upregulated within 1–2 h after brain ischemia25, a condition resulting in massive tissue 
necrosis that leads to sterile inflammation26. Both, cell damage and inflammation, also enable the release of NAD+ 
into the extracellular space where it could serve as substrate for ARTC2.127,28. Therefore, future experiments 
should investigate the expression of ARTC2.1 on microglia during brain ischemia. Based on the present findings, 
ARTC2.1 could potentially modulate the microglia response to sterile inflammation by ADP-ribosylating micro-
glia cell surface proteins involved in immune functions.
To identify potential targets of ARTC2.1 on microglia, we used a novel mass spectrometry based approach 
that includes enrichment of ADP-ribosylated peptides via the ADP-ribose binding macrodomain Af1521. With 
this approach we identified 40 cell surface proteins that were ADP-ribosylated in the presence of NAD+/DTT. 
Their ADP-ribosylation was strictly dependent on the enzymatic activity of ARTC2.1 as we could not detect 
any ADP-ribosylated peptides derived from ARTC2−/− microglia. However, it is worth noting that even though 
our novel approach provided important information regarding ARTC2.1 protein targets in microglia, we cannot 
Figure 4. MS/MS analyses of ADP-ribosylated peptides fragmented using HCD. (a) Experimental setup for the 
identification of ARTC2.1 target proteins in microglia. (b) The presented peptides belong to FcγR2B, which is 
ADP-ribosylated at R198 (left) and FcγR1, which is ADP-ribosylated at R184 (right). The ADP-ribose specific 
fragment is indicated in the spectrum in red and peptide sequence coverage is shown below the respective 
spectrum.
www.nature.com/scientificreports/
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gene protein protein accession
ADPR 
site
ADPR 
AA confidence peptide sequence
peptide 
score
expect 
value
Alcam CD166 antigen tr|E9Q3Q6|E9Q3Q6_MOUSE 319 R 100% (R)NMAASTTITVHYLDLSLNPSGEVTK 54 0,0015
Alcam CD166 antigen tr|E9Q3Q6|E9Q3Q6_MOUSE 386 D 99,85% LRSSPSFSSLHYQ(D)AGNYVCETALQEVEGLK 74,34 2,20E-07
Bcam Basal cell adhesion molecule sp|Q9R069|BCAM_MOUSE 484 D 96,83% LTWSQRG(D)TPAEPPFEGR 30,05 0,0031
Cd14 Monocyte differentiation antigen CD14 sp|P10810|CD14_MOUSE 68 R 100% (R)VDTEADLGQFTDIIK 132,14 2,00E-11
Cd40
Isoform V of Tumor necrosis 
factor receptor superfamily 
member 5
sp|P27512-5|TNR5_MOUSE 247 E 99,83% ISVQ(E)RQVTDSIALRPLV 52,58 1,20E-05
Cd9 CD9 antigen sp|P40240|CD9_MOUSE 131 R 96,99% L(R)SKDEPQR 27,61 0,0053
Clec12a C-type lectin domain family 12 member A sp|Q504P2|CL12A_MOUSE 197 D 100% K(D)RTQYPLSEK 32,74 0,0018
Clec12a C-type lectin domain family 12 member A sp|Q504P2|CL12A_MOUSE 215 R 97,79% MFLSEESE(R)STDDIDKK 27,02 0,0064
Enpp1
Ectonucleotide pyrophosphatase/
phosphodiesterase 1 isoform 
CRA_d
tr|G3 × 9S2|G3 × 9S2_MOUSE 853 R 100% (R)ESSWVEELLTLHR 96,1 7,40E-08
Enpp1
Ectonucleotide pyrophosphatase/
phosphodiesterase 1 isoform 
CRA_d
tr|G3 × 9S2|G3 × 9S2_MOUSE 854 E 99,31% R(E)SSWVEELLTLHR 63,12 1,50E-06
Fcer1g High affinity immunoglobulin epsilon receptor subunit gamma sp|P20491|FCERG_MOUSE 71 R 100,00% EKADAVYTGLNT(R)SQETYETLK 76,36 7,90E-06
Fcgr1 High affinity immunoglobulin gamma Fc receptor I sp|P26151|FCGR1_MOUSE 184 R 100% H(R)YTSAGVSITVK 40,29 0,00025
Fcgr2b Low affinity immunoglobulin gamma Fc region receptor II tr|E9Q415|E9Q415_MOUSE 198 R 100,00% GSLG(R)TLHQSKPVTITVQGPK 107,45 9,70E-11
Fcgr2b Low affinity immunoglobulin gamma Fc region receptor II tr|E9Q415|E9Q415_MOUSE 88 R 100% SI(R)SQVQASYTFK 61,23 1,80E-06
Fcgr2b Low affinity immunoglobulin gamma Fc region receptor II tr|E9Q415|E9Q415_MOUSE 158 R 100% LLN(R)ISFFHNEK 30,35 0,0016
H2-D1
Isoform 2 of H-2 class I 
histocompatibility antigen alpha 
chain
sp|P01895-2|HA1Y_MOUSE 7 R 100% A(R)WIEQEGPEYWER 77,61 4,10E-06
H2-K1 H-2 class I histocompatibility antigen K-D alpha chain sp|P01902|HA1D_MOUSE 169 E 98,50% RKW(E)QAGDAEYYR 31,46 0,0011
Hfe Hemochromatosis isoform CRA_a tr|Q5SZ87|Q5SZ87_MOUSE 120 E 100% LL(E)LGRGVLGQQVPTLVK 47,31 7,20E-05
Icam1 Isoform 2 of Intercellular adhesion molecule 1 sp|P13597-2|ICAM1_MOUSE 345 R 99,86% VVLLSGVEP(R)PPTPQVQFTLNASSEDHKR 35,05 0,00054
Icam1 Isoform 2 of Intercellular adhesion molecule 1 sp|P13597-2|ICAM1_MOUSE 152 R 99,02% GEEILS(R)QPVGGHPK 27,87 0,0057
Icoslg Isoform 2 of ICOS ligand sp|Q9JHJ8-2|ICOSL_MOUSE 108 R 100% N(R)GHLSLDSMK 30,38 0,0029
Il2rg Cytokine receptor common subunit gamma sp|P34902|IL2RG_MOUSE 196 R 100% D(R)SWTELIVNHEPR 41,46 0,00013
Itga5 Integrin alpha-5 sp|P11688|ITA5_MOUSE 903 R 100% EAPG(R)SSTASGTQVLK 25,81 0,0064
Itga6 Integrin alpha-6 (Fragment) tr|F6VSK8|F6VSK8_MOUSE 188 R 100% LRPIPITASVEIQEPSS(R) 69,51 2,70E-05
Itgam Integrin alpha-M tr|Q3U1U4|Q3U1U4_MOUSE 415 R 100% N(R)VQSLVLGAPR 51,11 2,00E-05
Itgam Integrin alpha-M tr|Q3U1U4|Q3U1U4_MOUSE 502 R 100% A(R)WQCEALLHGDQGHPWGR 94,4 1,20E-07
Itgam Integrin alpha-M tr|Q3U1U4|Q3U1U4_MOUSE 277 R 99,18% FGDPLDYKDVIPEAD(R)AGVIR 50,86 4,20E-05
Itgam Integrin alpha-M tr|Q3U1U4|Q3U1U4_MOUSE 506 E 95,00% ARWQC(E)ALLHGDQGHPWGR 30,38 0,0017
Itgav Integrin alpha-V light chain tr|A2AKI5|A2AKI5_MOUSE 855 R 100% DLTL(R)EGDVHTLGCGIAK 60,04 0,00031
Itgb1 Isoform 2 of Integrin beta-1 sp|P09055-2|ITB1_MOUSE 228 R 100% NVLSLTD(R)GEFFNELVGQQR 55,9 7,50E-06
Itgb2 Integrin beta tr|Q542I8|Q542I8_MOUSE 454 R 100% DQS(R)EQSLCGGK 41,49 0,0002
Itgb5 Integrin beta tr|Q6PE70|Q6PE70_MOUSE 226 R 100% HLLPLTD(R)VDSFNEEVRK 30,98 0,0013
Itgb5 Integrin beta tr|Q6PE70|Q6PE70_MOUSE 72 R 100% ANLI(R)NGCEGEIESPASSTHVLR 84,68 1,30E-06
Itgb5 Integrin beta tr|Q6PE70|Q6PE70_MOUSE 158 R 99,85% DDLENI(R)SLGTK 39,92 0,031
Lgals1 Galectin-1 sp|P16045|LEG1_MOUSE 116 E 99,97% FPNRLNM(E)AINYMAADGDFK 42,7 0,00015
Lrpap1 Alpha-2-macroglobulin receptor-associated protein sp|P55302|AMRP_MOUSE 71 R 100% (R)LHLSPVR 20,46 0,012
Mcam Isoform 2 of Cell surface glycoprotein MUC18
sp|Q8R2Y2-2|MUC18_
MOUSE 71 R 100% E(R)QILIFR 39,14 0,0066
Mrc1 Macrophage mannose receptor 1 sp|Q61830|MRC1_MOUSE 545 R 100,00% AYLTTVED(R)YEQAFLTSLVGLRPEK 85,03 1,10E-08
Pdia3 Protein disulfide-isomerase A3 sp|P27773|PDIA3_MOUSE 62 R 100% (R)LAPEYEAAATR 63,08 0,00013
Ptprc Receptor-type tyrosine-protein phosphatase C tr|S4R1M0|S4R1M0_MOUSE 168 R 100% (R)NTFIPER 24,41 0,0051
Continued
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exclude that some ADP-ribosylated proteins were not detected using this technique. For instance, the P2X7 recep-
tor (P2rx7), a known target for ARTC2-mediated ADP-ribosylation on macrophages and on T cells29, is expressed 
on microglia (Fig. S1a), but the corresponding ADP-ribosylated peptide was not detected using our mass spec-
trometry method. In contrast, immunoprecipitation of P2X7 from 32P-NAD+/DTT treated microglia and subse-
quent autoradiography confirmed that P2X7 is also a target for ADP-ribosylation on microglia (Fig. S1b). Hence, 
even though enrichment of ADP-ribosylated peptides by macrodomain Af1521 and subsequent mass spectrome-
try analyses displayed a very powerful approach to define a cell surface “ADP-ribosylome”, some ADP-ribosylated 
target proteins could be left unnoticed due to technical constraints.
Further investigations are needed to define the functional impact of ADP-ribosylation on the newly identi-
fied ARTC2.1 targets on microglia. It is likely that ADP-ribosylation impairs the function of some of the newly 
identified targets. Recently we could show that ADP-ribosylation of the interleukin 2 (IL-2) receptor alpha chain 
(CD25) on regulatory T cells (Tregs) affects the binding of IL-2 and thereby diminished Treg STAT5 phospho-
rylation and proliferation15. In a proof-of-principle experiment we evaluated the impact of ADP-ribosylation on 
immunoglobulin binding by FcγRs on microglia, since the ADP-ribosylation sites we identified were in close 
proximity to the receptor binding sites for IgG Fc fragments. Indeed, we observed that ADP-ribosylation of 
FcγR1 and FcγR2B affected IgG binding to microglia. FcγR1 and FcγR2B have opposing biological roles in 
microglia: the high affinity FcγR1 triggers microglia activation and promotes phagocytosis and the release of 
inflammatory mediators. Conversely, the low affinity FcγR2B elicits counteracting inhibitory signals30. Since 
ADP-ribosylation reduced IgG binding to both FcγRs, the overall biological effect of ADP-ribosylation on micro-
glial FcγRs under inflammatory conditions in the brain (e.g. ischemic stroke) needs to be further investigated. 
Interestingly, FcγR−/− mice show significantly reduced microglia activation and smaller infarct sizes compared 
to WT mice in the middle cerebral artery occlusion (MCAO) mouse model for ischemic stroke31. Therefore, it is 
conceivable that ADP-ribosylation of FcγR could represent a protective physiological mechanism to control the 
activation of microglia during sterile inflammation in mice. However, it must be noted that the direct transfer of 
this newly discovered mechanism from mouse to human microglia remains unclear, as functional ARTC2 does 
not exist in humans due to a premature stop codon32. Therefore, it will be necessary to analyze human microglia 
for the expression of other cell surface ADP-ribosyltransferases that could serve to mediate cell surface ART 
activity.
In conclusion, we identified ARTC2.1 as major ecto-ART expressed by microglia and identified multiple new 
ADP-ribosylation targets of the microglia cell surface by mass spectrometry thus defining a microglia cell surface 
“ADP-ribosylome”. It will be necessary to further analyze the functional impact of ADP-ribosylation on each 
identified target, as we did in a proof-of-principle experiment for FcγRs. This will provide further insights into the 
regulatory role of this post-translational modification during inflammation. Finally, our approach could be used 
to define the cell surface “ADP-ribosylome” of other ARTC2-expressing immune cell populations such as T cells.
gene protein protein accession
ADPR 
site
ADPR 
AA confidence peptide sequence
peptide 
score
expect 
value
Ptprc Receptor-type tyrosine-protein phosphatase C tr|S4R1M0|S4R1M0_MOUSE 508 R 100% N(R)YVDILPYDYNR 42 0,015
Ptprj Receptor-type tyrosine-protein phosphatase eta sp|Q64455|PTPRJ_MOUSE 202 R 100% (R)IPVTNLSQLHK 29,43 0,0017
Pvrl2 Isoform Alpha of Nectin-2 sp|P32507-2|PVRL2_MOUSE 104 R 100% A(R)PETNADLR 20 0,037
Sdc3 Syndecan-3 sp|Q64519|SDC3_MOUSE 362 D 98,15% GARPGPGLH(D)NAIDSGSSAAQLPQK 45,2 0,00037
Sdc4 Syndecan-4 sp|O35988|SDC4_MOUSE 116 R 100% (R)APSDVGDDMSNK 35,64 0,023
Slamf7 Isoform 4 of SLAM family member 7 sp|Q8BHK6-4|SLAF7_MOUSE 77 R 100% E(R)IVFPDGLYSMK 20,04 0,013
Slc3a2 Isoform 2 of 4F2 cell-surface antigen heavy chain sp|P10852-2|4F2_MOUSE 509 R 100% SA(R)LGASNLPAGISLPASAK 52,26 0,00024
Slc3a2 Isoform 2 of 4F2 cell-surface antigen heavy chain sp|P10852-2|4F2_MOUSE 168 R 99,99% IGDLQAFVG(R)DAGGIAGLK 46,05 0,0073
Slc9a1 Sodium/hydrogen exchanger 1 sp|Q61165|SL9A1_MOUSE 622 R 100% AVTSD(R)ILPALSK 33,64 0,005
Stx4 Syntaxin-4 sp|P70452|STX4_MOUSE 192 D 99,99% (D)TQVTRQALNEISAR 52,29 2,90E-05
Tfrc Transferrin receptor protein 1 sp|Q62351|TFR1_MOUSE 658 R 100% ATS(R)LTTDFHNAEK 31,69 0,007
Tfrc Transferrin receptor protein 1 sp|Q62351|TFR1_MOUSE 358 R 100% MEGSCPA(R)WNIDSSCK 41,06 0,029
Tlr2 Toll-like receptor tr|G3 × 8Y8|G3 × 8Y8_MOUSE 187 R 100% ALSL(R)NYQSQSLK 32,78 0,0011
Vamp3 Vesicle-associated membrane protein 3 sp|P63024|VAMP3_MOUSE 18 R 100% (R)LQQTQNQVDEVVDIMR 57,88 0,00054
Table 1. List of ADP-ribosylated peptides identified from LPS/U0126 stimulated microglia. Mixed glial cells 
were stimulated with LPS (0.1 µg/ml) and U0126 (10 µM) overnight in BME medium containing 10% FCS. 
CD11b+ microglia were FACS sorted, incubated with 50 µM NAD and 2.5 mM DTT for 30 min on ice, washed 
twice with PBS and lysed using RIPA buffer. After trypsin digestion ADPR peptides were enriched using 
macrodomain Af1521 and samples were subjected to mass spectrometry analyses. Only peptides of cell surface 
proteins displaying a peptide score >20 and a confidence of >95% were included into the analyses.
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Material and Methods
Mice. ARTC2−/−, ARTC2.1−/− and ART2.2−/− mice33 were backcrossed onto the BALB/c background for at 
least 12 generations. All mice were bred at the animal facility of the University Medical Center (UKE). All exper-
iments involving tissue derived from animals were performed with approval of the responsible regulatory com-
mittee (Hamburger Behörde für Gesundheit und Verbraucherschutz, Veterinärwesen/Lebensmittelsicherheit, 
ORG-722). All methods were performed in accordance with the relevant guidelines and regulations.
Mixed glial cell cultures and stimulation with LPS/U0126 or IFNβ. The brains of 1 to 2 days old 
neonatal mice were prepared and transferred into Hanks Balanced Salt Solution (HBSS, ThermoFisher) con-
taining 10 mM HEPES (ThermoFisher). After removal of the meninges, brains were minced, washed and incu-
bated for 25 min in HBSS + 10 mM HEPES with 0.5 mg/ml papain (Sigma-Aldrich) and 10 μg/ml DNAse (Roche 
Diagnostics). Cells were washed again in BME medium (Life Technologies), dissociated and then plated at a 
density of 3 × 105 cells/ml and cultured in BME media supplemented with 10% FCS and penicillin/streptomycin. 
Cells were used for analyses after 21 days of culture and contained 20–30% microglia and 60–70% astrocytes. 
Cells were stimulated with LPS (0.1 µg/ml, Sigma-Aldrich) and U0126 (10 µM, Sigma-Aldrich) or with 1–1000 U/
ml recombinant mouse IFNβ (BioLegend) for 24 h before ADP-ribosylation assays.
Figure 5. ADP-ribosylation of FcγRs affects binding of IgG to transfected HEK cells. (a) Using SWISS-
MODEL, the structures of mouse FcγR1 and FcγR2B 3D structures were modeled on the corresponding 
structures of human FcγR1 (pdb: 4w4o) and FcγR2B (pdb: 3wjj) in complex with human IgG1-Fc. FcγRs are 
displayed in cyan, the Fc portion of IgG1 is shown in yellow. ARTC2.1 target arginines are labeled in red. (b) 
Soluble FcγR1 and FcγR2B were radiolabeled with 32P-NAD+ (1 µM) by soluble ARTC2.1 in the presence or 
absence of DTT (2.5 mM) and the ARTC inhibitor novobiocin. Proteins were fractioned by SDS-PAGE and 
subjected to autoradiography (cropped). (c) Binding of human intravenous immunoglobulins (IVIGs) to ADP-
ribosylated or unmodified FcγR1 and FcγR2B was measured in a thermophoresis assay starting with an IVIG 
concentration of 50 mg/ml and 1:2 dilution steps. Each dot represents the mean of 4 measurements. (d) HEK 
cells were transfected with FcγR1 or FcγR2B alone or in combination with ARTC2.1. (e) Ecto-ART activity in 
FcγRs/ARTC2.1 co-transfected HEK cells was measured after incubation with or without eNAD+/DTT. (f) 
HEK cells transfected with FcγR1/FcγR2B or co-transfected with ARTC2.1 were pre-incubated with or without 
100 µM NAD+ and 2 mM DTT. Cells were washed and incubated with BALB/c mouse serum (1:20 diluted) 
and cell surface binding of mouse IgG was measured using a PE-conjugated anti-mouse IgG F(ab)2. Data are 
representative of 2–3 independent experiments.
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Antibodies and flow cytometry. Cells were analyzed using BD FACSCanto II following staining with 
fluorochrome-conjugated mAbs: anti-CD3 (clone 145-2C11, Biolegend), anti-ARTC2.1 (clone R18A136#2; UKE), 
anti-ARTC2.2 (clone Nika109; UKE), anti-etheno-ADP-ribose (clone 1G4, UKE)34, anti-CD11b (clone M1/70; 
BioLegend), anti-GLAST (clone ACSA-1; Miltenyi), anti-FcγR1 (clone  X54-5/7.1, BioLegend) and anti-FcγR2B 
(clone AT130-2, eBioscience), anti-P2X7 (clone RH23A44, UKE), donkey anti-mouse IgG F(ab)2 (Dianova). For 
flow cytometric analyses, spleen T cells were identified as CD3+, spleen macrophages as F4/80+ cells. Microglia 
were identified as CD11b+GLAST− cells and astrocytes as CD11b−GLAST+. For the detection of mouse IgG on 
the cell surface of the microglia or transfected HEK cells, cells were incubated with fresh BALB/c mouse serum 
(1:20 dilution), washed twice and IgG binding was detected with a PE-conjugated donkey-anti mouse IgG F(ab)2.
For some experiments microglia and astrocytes were sorted at the FACS Core Facility at the University 
Medical Center Hamburg-Eppendorf (UKE) on a BD FACSAria III. Analysis of flow cytometric data was per-
formed using FlowJo (Miltenyi Biotec).
Etheno-ADP-ribosylation assay. Cultured glial cells or splenocytes were incubated for 20 min at 4 °C 
with 100 µM etheno-nicotinamide adenine dinucleotide (eNAD+, Sigma-Aldrich) in the presence or absence of 
2–5 mM dithiothreitol (DTT, Invitrogen). eNAD+ was then removed by washing cells twice with PBS, 1% fetal 
calf serum (FCS, Gibco). Etheno-ADP-ribose incorporated into cell surface proteins was detected as described 
previously20 using fluorochrome-conjugated etheno-adenosine-specific monoclonal antibody 1G4. Cells were 
washed with PBS, 1% FCS and analyzed by flow cytometry. Cells that were not treated with eNAD+ were stained 
with 1G4 and used as control.
32P-NAD+ ADP-ribosylation assay. Radio-ADP-ribosylation of cell surface proteins was performed as 
described previously15,27 using either mixed cultured glial cells or FACS-sorted microglia or astrocytes. Cells were 
incubated with 1 µM 32P-NAD+ for 15 min at 37 °C in the absence or presence of 5 mM DTT. Cells were washed 
4 times at 4 °C in PBS and cell membrane proteins were then solubilized with 1% Triton X-100 in PBS containing 
Figure 6. ADP-ribosylation of FcγRs affects binding of IgG to microglia. (a) IgG binding to unstimulated, 
LPS/U0126-stimulated (upper plot) or IFNβ-stimulated (lower plot) microglia was analyzed by flow 
cytometry. Cells were pre-incubated with NAD+/DTT or left untreated, washed twice with PBS and were 
incubated with IgG containing mouse serum (1:20 diluted) for 30 min. Cells were washed twice and cell 
surface binding of mouse IgG was measured using a PE-conjugated anti-mouse IgG F(ab)2. (b) Phagocytosis 
of PE-labeled IgG-coated latex beads by unstimulated, LPS-stimulated or IFNβ-stimulated microglia from 
WT or ARTC2.1−/− mice was measured by flow cytometry. Cells were either preincubated with DTT alone or 
with NAD+/DTT for 30min, washed twice and allowed to phagocytose IgG-beads for 3h. Phagocytosis 
rate was normalized to the corresponding DTT control sample (100%).  Data are representative of 2–3 
independent experiments. Statistical comparison of two groups was performed by using the student’s t test 
(p < 0.05 = */p < 0.01 = **/p < 0.001 = ***).
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2 µM PARP-inhibitor PJ-34 (ENZO Life Sciences) for 30 min at 4 °C. Cell lysates were clarified from nuclei and 
other insoluble proteins by high-speed centrifugation. Proteins were size fractionated by SDS-PAGE and stained 
with Coomassie, radiolabeled proteins were detected by autoradiography.
Quantitative real-time PCR. RNA was extracted from FACS sorted microglia using RNeasy® Plus Mini 
Kit (Qiagen) followed by cDNA synthesis using the Maxima First Strand cDNA Synthesis Kit (Thermo Fisher 
Scientific) as recommended by the respective supplier.
Taqman probes (ThermoFisher Scientific) for mouse Art2a (Mm01269252_m1) and mouse Ifnb1 (Mm00439552_
s1) were used for quantitative real-time PCR and measured on a Lightcycler 96 (Roche). The relative gene expression 
was calculated using the ΔΔCt method. Samples were normalized to the expression of the housekeeping gene Sdha 
(Mm01352366_m1). Untreated samples were used as calibrator and compared to LPS/U0126 stimulated samples.
IFNβ ELISA. IFNβ secretion by mixed glial cells upon stimulation with LPS/U0126 was measured using a 
commercially available mouse IFNβ ELISA kit (Biolegend). ELISA was performed according to the manufactur-
er’s instructions.
Enrichment of ADP-ribosylated peptides. Microglia cells were lysed in RIPA buffer (Sigma-Aldrich), 
supplemented with Roche complete (1x), Pefa (AEBSF, 4 µM, Sigma-Aldrich), Novobiocin (200 µM, 
Sigma-Aldrich) and PJ34 (PARP inhibitor, 2 µM, Sigma-Aldrich). To process and digest the samples we used 
trypsin digestion and a filter-aided sample preparation (FASP) method. Samples containing 250 µg proteins were 
diluted and reduced in Urea Buffer (8 M Urea, 0.1 M Tris-HCl pH 8) containing 1 mM DTT, transferred to a 
Microcon-30-kDa-cutoff centrifugal filter unit (Millipore), centrifuged at 14,000 g at 20 °C for 20 min and washed 
with 200 µl urea buffer. Samples were alcylated using urea buffer containing 20 mM chloroacetamide and washed 
two times with 100 μl urea buffer and three times with 100 µl 50 mM ammonium bicarbonate. The on filter diges-
tion was performed in 50 mM ammonium bicarbonate using a 1:50 protein to sequencing grade modified trypsin 
(Promega) ratio overnight at room temperature.
ADP-ribosylated peptide enrichment was performed as previously described18. The peptide mixture was 
diluted in IP buffer (50 mM Tris–HCl, pH 8, 10 mM MgCl2, 250 μM DTT and 50 mM NaCl) and binding was 
carried out for 2 h at 4 °C using the Af1521 macrodomain GST-fusion protein coupled to glutathione-Sepharose 
beads. Beads were washed three times with IP buffer and bound peptides were eluted with 0.15% TFA. The result-
ing mixture was desalted using stage tips packed with C18 filters.
Liquid chromatography and mass spectrometry analysis. All data were acquired on an Orbitrap 
Q-Excative HF mass spectrometer (Thermo Fisher Scientific) connected to a nano EasyLC 1000 HPLC system 
(Thermo Fisher Scientific). 4 µl of peptide sample in 0.1% formic acid and 3% acetonitrile are loaded onto a self-made 
column (75 µm × 150 mm) packed with reverse-phase C18 material (ReproSil-Pur 120 C18-AQ, 1.9 µm, Dr. Maisch 
GmbH) and separated at a flow rate of 300 nL/min by a gradient from 2 to 25% B in 90 minutes. Solvent composition at 
the channels A and B was 0.1% formic acid and 0.1% formic acid, 99.9% acetonitrile, respectively. The mass spectrome-
ter was set to acquire full-scan MS spectra (300–1700 m/z) at a resolution of 60’000 after accumulation to an automated 
gain control (AGC) target value of 3e6. Charge state screening was enabled, and unassigned charge states, and single 
charged precursors were excluded. Ions were isolated using a quadrupole mass filter with a 2 m/z isolation window. 
A maximum injection time of 240 ms was set. HCD fragmentation was performed at a normalized collision energy 
(NCE) of 28%. Selected ions were dynamically excluded for 20 sec.
Database Analyses and Configuration of Mascot Modifications. The raw file processing and the data-
base search using Mascot was performed as described in35. Briefly, MS and MS/MS spectra were converted to Mascot 
generic format (MGF) using Proteome Discoverer, v2.1 (Thermo Fisher Scientific). The MGFs were searched against 
the UniProtKB mouse database (taxonomy 10090, version 20160902), which included 24905 Swiss-Prot, 34616 
TrEMBL entries, 59783 decoy hits, and 262 common contaminants. Mascot 2.5.1.3 (Matrix Science) was used for 
peptide sequence identification. A peptide tolerance was set to 10 ppm and MS/MS tolerance was 0.05 Da. Enzyme 
specificity is set to trypsin, allowing up to 4 missed cleavages. The ADP-ribose variable modification was set to a mass 
shift of 541.0611, with scoring of the neutral losses equal to 347.0631 and 249.0862. The marker ions at m/z 428.0372, 
348.0709, 250.0940, 136.0623 are ignored for scoring. R, K, D and E are set as variable ADP-ribose acceptor sites. 
Carbamidomethylation is set as a fixed modification on C and oxidation as a variable modification on M. Peptides are 
considered correctly identified when a Mascot score >20 and an expectation value <0.05 are obtained.
Microscale thermophoresis assay for IgG binding to FcγRs. To evaluate the impact of ADP-ribosylation 
on FcγRs, we used microscale thermophoresis to quantify biomolecular interactions. We labeled recombinant FcγR1 
(Sino Biological) and FcγR2B (Sino Biological) with Monolith Protein Labeling Kit RED-NHS (NanoTemper tech-
nologies) according to the manufacturer’s instructions. Labeled FcγR1 and FcγR2B were then coincubated with a 1:2 
dilution series (12 steps) of human intravenous immunoglobulins (IVIGs, Privigen) starting at 50 mg/ml. For binding 
analyses the mixture was absorbed into Monolith NT.115 MST Premium Coated Capillaries (NanoTemper technolo-
gies) and FcγR binding to human IgG was analyzed on the Monolith NT.115 instrument (NanoTemper technologies) 
using the sequence 5 sec baseline, 30 sec IR laser on, 5 sec IR laser off. The normalized mean fluorescence signal of 4 
measurements was plotted against the concentration of unlabeled IVIGs.
Recombinant expression of FcγRs and ARTC2.1 in HEK cells. Codon-optimized open read-
ing frames encoding for mouse FcγR1 (UniProtKB P26151) and FcγR2B (NCBI Reference Sequence: 
NP_001070657.1), flanked by EcoRI and NotI restriction sites were synthesized by GeneArt (Invitrogen) and 
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cloned into the pCMVSport6.1 vector. Expression constructs were transfected into human embryonic kidney 
(HEK) cells using jetPEI transfection reagent (Q-Biogen). FcγR expression constructs were either transfected 
alone or co-transfected with pCMVSport6.1 encoding for ARTC2.1 kindly provided by Prof. Koch-Nolte.
Phagocytosis assay. Adherent mixed glial cells from WT and ARTC2.1−/− mice were stimulated with LPS/
U0126 or IFNβ to induce ecto-ART activity in microglia, or left unstimulated. Cells were then pre-incubated 
with 100 µM NAD+/2 mM DTT or 2 mM DTT alone in 24-well plates for 30 min on ice. Cells were washed twice 
with 500 µl PBS to remove the NAD+/DTT and were incubated with PE-labeled IgG-coated latex beads (Cayman 
Chemical) at a dilution of 1:200 in BME 10% FCS medium at 37 °C. Mixed glial cells were allowed to phagocytose 
for 3 h, then the phagocytic activity of microglia was evaluated by flow cytometry. For the analyses, phagocytic 
activity was normalized to controls that were pre-incubated only with DTT (100%).
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